CodeMap® Compliance Briefing: February 10, 2023

Editor's Welcome:

According to the latest OIG Data Brief, the Medicare Part B Program spent $9.3 billion on clinical lab tests in 2021. Genetic tests (molecular pathology tests, multianalyte algorithmic assays, genomic sequencing procedures, and proprietary lab analysis tests) increased by 56% which is an increase of $677 million over 2020 spending.   The OIG noted concern for the number of chemistry tests, as the numbers declined to below the pre-pandemic levels. Below is a synopsis of the OIG report from Jondavid Klipp of Laboratory Economics.  As always, please forward any questions, comments, and/or suggestions to us via email.

<....

Sorry, access to this content requires a current subscription.

Click here for publications catalog.

CPT copyright 2024 American Medical Association. All rights reserved.

* The responsibility for the content of any "National Correct Coding Policy" included in this product is with the Centers for Medicare and Medicaid Services and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable to or related to any use, nonuse, or interpretation of information contained in this product.